Yuhan Corporation
Clinical trials sponsored by Yuhan Corporation, explained in plain language.
-
New drug YH42946 targets Hard-to-Treat lung and solid tumors
Disease control Recruiting nowThis study tests a new drug called YH42946 in people with advanced solid tumors (including lung cancer) that have certain gene changes (HER2 or EGFR). The main goals are to check safety, how the drug moves through the body, and whether it shrinks tumors. About 161 participants wh…
Phase: PHASE1, PHASE2 • Sponsor: Yuhan Corporation • Aim: Disease control
Last updated May 26, 2026 05:44 UTC
-
New drug takes on hard-to-treat HER2 cancers in first human test
Disease control Recruiting nowThis study is the first time a new drug called YH32367 is being tested in people. It aims to see if the drug is safe and can shrink tumors in patients with advanced HER2-positive solid cancers that have spread. About 147 adults with these cancers will take part. The study is not …
Phase: PHASE1, PHASE2 • Sponsor: Yuhan Corporation • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
New hope for chronic hives sufferers: experimental drug lesigercept in human trials
Symptom relief Recruiting nowThis study tests a new drug called lesigercept for people with chronic spontaneous urticaria (long-term hives) that antihistamines don't fully control. About 150 adults will receive either the drug or a placebo for 12 weeks to see if it reduces itching and welts. The goal is to f…
Phase: PHASE2 • Sponsor: Yuhan Corporation • Aim: Symptom relief
Last updated May 15, 2026 11:53 UTC
-
Healthy men needed for first human test of new drug YH35995
Knowledge-focused Recruiting nowThis early-stage study tests the safety of a new drug called YH35995 in 86 healthy adult men. Participants receive either the drug or a placebo to see how the body processes it and if any side effects occur. The goal is to gather important safety information, not to treat any dis…
Phase: PHASE1 • Sponsor: Yuhan Corporation • Aim: Knowledge-focused
Last updated May 22, 2026 13:55 UTC